Arrowstreet Capital Limited Partnership Raises Stake in Danaher Corporation $DHR

Arrowstreet Capital Limited Partnership increased its holdings in shares of Danaher Corporation (NYSE:DHR) by 0.3% during the 1st quarter, HoldingsChannel reports. The fund owned 3,639,630 shares of the conglomerate’s stock after buying an additional 11,578 shares during the period. Arrowstreet Capital Limited Partnership’s holdings in Danaher were worth $690,074,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of DHR. Caxton Associates LLP purchased a new stake in Danaher during the 1st quarter valued at about $1,064,000. Spear Holdings RSC Ltd purchased a new stake in shares of Danaher during the first quarter valued at approximately $52,917,000. PBCay One RSC Ltd purchased a new stake in Danaher during the 1st quarter valued at $52,917,000. Forefront Analytics LLC increased its holdings in shares of Danaher by 40.8% in the 1st quarter. Forefront Analytics LLC now owns 1,288 shares of the conglomerate’s stock worth $244,000 after purchasing an additional 373 shares in the last quarter. Finally, CI Investments Inc. boosted its position in shares of Danaher by 2.3% during the first quarter. CI Investments Inc. now owns 1,181,493 shares of the conglomerate’s stock valued at $224,011,000 after buying an additional 26,367 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Up 7.5%

DHR opened at $192.52 on Friday. The stock has a market cap of $135.34 billion, a price-to-earnings ratio of 34.20, a price-to-earnings-growth ratio of 2.19 and a beta of 0.79. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.52 and a current ratio of 1.65. The firm’s fifty day moving average is $185.05 and its 200 day moving average is $197.07. Danaher Corporation has a fifty-two week low of $160.93 and a fifty-two week high of $242.80.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, July 21st. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. The business had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%.Danaher’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.77 EPS. On average, sell-side analysts forecast that Danaher Corporation will post 8.51 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Friday, June 26th will be given a dividend of $0.40 per share. The ex-dividend date is Friday, June 26th. This represents a $1.60 annualized dividend and a dividend yield of 0.8%. Danaher’s dividend payout ratio (DPR) is presently 30.95%.

More Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Several commentary pieces say the post-earnings drop may have created a buying opportunity, with Barron’s arguing investors should not abandon Danaher (DHR) after the sharp reaction and suggesting the stock could rebound. Article: Don’t Quit on Danaher Stock After Horrific Earnings Reaction
• Positive Sentiment: One technical-market update said the selloff may be showing signs of capitulation, and noted some bullish trading activity in the shares, which could indicate downside pressure is easing. Article: Stock Of The Day: Is The Danaher Selloff Over?
• Positive Sentiment: Wall Street analysts still see meaningful upside from current levels, with one note highlighting a consensus price target implying about 32% potential gain and improving earnings estimate revisions. Article: Can Danaher (DHR) Climb 32.39% to Reach the Level Wall Street Analysts Expect?
• Neutral Sentiment: Danaher’s Q2 2026 earnings call transcript was published, giving investors a fresh look at management’s commentary and the company’s outlook, but the transcript itself does not change fundamentals. Article: Danaher (DHR) Q2 2026 Earnings Call Transcript
• Neutral Sentiment: Unusual options activity showed elevated put buying in Danaher (DHR), suggesting some traders are hedging for further downside or volatility after the earnings-driven move.
• Negative Sentiment: Recent coverage says the stock’s sharp decline was driven by Q2 results where a beat on earnings was overshadowed by bioprocessing weakness and analyst price-target cuts, which remain the main bearish overhang on the shares. Article: Stock Of The Day: Is The Danaher Selloff Over?

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on DHR. Argus decreased their price objective on shares of Danaher from $265.00 to $230.00 and set a “buy” rating for the company in a report on Friday, April 24th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $240.00 price target on shares of Danaher in a research report on Wednesday. Royal Bank Of Canada increased their price objective on shares of Danaher from $200.00 to $215.00 and gave the stock an “outperform” rating in a research note on Wednesday. HSBC dropped their price objective on shares of Danaher from $270.00 to $230.00 and set a “buy” rating on the stock in a report on Wednesday, June 3rd. Finally, Piper Sandler initiated coverage on shares of Danaher in a report on Thursday, June 11th. They set a “neutral” rating and a $200.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and a consensus target price of $228.91.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.